{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-041394","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2023-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.775678+00:00","generated_at":"2026-06-07T13:18:17.902708+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sangamo/Pfizer Alta study: 4-year data shows mean ABR 1.4, sustained FVIII activity","bullets":["Cohort 4 (3e13 vg/kg) mean ABR 1.4, median 0.0; 3 of 5 participants had zero bleeds post-infusion.","FVIII activity maintained in mild-to-normal range in 4 of 5 participants over 4-year follow-up; 1 participant had FVIII BLOQ.","No new safety signals; no thrombotic, neoplastic events, or FVIII inhibitors; LFT elevations resolved with steroids.","Pfizer expects pivotal Phase 3 AFFINE readout mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-041394","json":"https://secwatch.observer/filing/0001628280-23-041394.json","markdown":"https://secwatch.observer/filing/0001628280-23-041394.md","text":"https://secwatch.observer/filing/0001628280-23-041394.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023041394/0001628280-23-041394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023041394/sgmo-20231211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:18:17.902708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}